The Roskamp Institute has received an award from the James & Esther King Biomedical Research Program grant for your project titled “Treatment of Lung Adenocarcinoma and Metastasis by Anti-angiogenic Fragments of Abeta.” The award was based on the scientific merit assigned to the proposal by qualified peer reviewers and other factors considered by the Biomedical Research Advisory Council. The official award letter came from the State Surgeon General Ana M. Viamonte Ros. Roskamp Institute researchers have previously shown that the Abeta peptide (also known as amyloid and which causes Alzheimer’s when it accumulates in the brain) is particularly good at stopping blood vessel growth to tumors. The Roskamp Institute researchers have shown that lung cancer growth is severely inhibited by the Abeta peptide. The funding from the state which was awarded after a peer review of the proposal will allow the development of the original findings towards clinical trials with the peptides. The research team are not concerned that if Abeta is used as a treatment for lung cancer it will cause Alzheimer’s because the small protein has in fact been given in human clinical trials as a vaccine prevention of Alzheimer’s.